While MDM2 overexpression typically promotes p53 degradation and oncogenesis, recent studies reveal context-dependent roles: in p53-mutant ALL, MDM2 may instead degrade pro-survival proteins like NF-κB or stabilize p73, an apoptotic effector (17). This evidence concerns the gene NFKB1 and acute lymphoblastic leukemia.